These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20425315)

  • 1. What signals are generated by anti-CD20 antibody therapy?
    Bonavida B
    Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
    Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
    Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.
    Shan D; Ledbetter JA; Press OW
    Cancer Immunol Immunother; 2000 Mar; 48(12):673-83. PubMed ID: 10752475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab.
    Dijoseph JF; Dougher MM; Armellino DC; Kalyandrug L; Kunz A; Boghaert ER; Hamann PR; Damle NK
    Cancer Immunol Immunother; 2007 Jul; 56(7):1107-17. PubMed ID: 17160682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
    Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
    Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
    De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
    Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mechanisms of action of rituximab in the elimination of tumor cells.
    Johnson P; Glennie M
    Semin Oncol; 2003 Feb; 30(1 Suppl 2):3-8. PubMed ID: 12652458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD59 inhibitor sensitizes rituximab-resistant lymphoma cells to complement-mediated cytolysis.
    Hu W; Ge X; You T; Xu T; Zhang J; Wu G; Peng Z; Chorev M; Aktas BH; Halperin JA; Brown JR; Qin X
    Cancer Res; 2011 Mar; 71(6):2298-307. PubMed ID: 21252115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines.
    Cittera E; Onofri C; D'Apolito M; Cartron G; Cazzaniga G; Zelante L; Paolucci P; Biondi A; Introna M; Golay J
    Cancer Immunol Immunother; 2005 Mar; 54(3):273-86. PubMed ID: 15449038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.
    Peng W; Zhang X; Mohamed N; Inghirami G; Takeshita K; Pecora A; Nardone LL; Pincus SE; Casey LS; Spitalny GL
    Cancer Immunol Immunother; 2005 Dec; 54(12):1172-9. PubMed ID: 15846490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.
    Bobrowicz M; Kusowska A; Krawczyk M; Zhylko A; Forcados C; Slusarczyk A; Barankiewicz J; Domagala J; Kubacz M; Šmída M; Dostalova L; Marhelava K; Fidyt K; Pepek M; Baranowska I; Szumera-Cieckiewicz A; Inderberg EM; Wälchli S; Granica M; Graczyk-Jarzynka A; Majchrzak M; Poreba M; Gehlert CL; Peipp M; Firczuk M; Prochorec-Sobieszek M; Winiarska M
    Oncoimmunology; 2024; 13(1):2362454. PubMed ID: 38846084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective clearance of rituximab-resistant tumor cells by breaking the mirror-symmetry of immunoglobulin G and simultaneous binding to CD55 and CD20.
    Lee SM; Min SW; Kwon HS; Bae GD; Jung JH; Park HI; Lee SH; Lim CS; Ko BJ; Lee JC; Jung ST
    Sci Rep; 2023 Oct; 13(1):18275. PubMed ID: 37880350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
    Terui Y; Sakurai T; Mishima Y; Mishima Y; Sugimura N; Sasaoka C; Kojima K; Yokoyama M; Mizunuma N; Takahashi S; Ito Y; Hatake K
    Cancer Sci; 2006 Jan; 97(1):72-9. PubMed ID: 16367924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of novel humanized anti-CD20 antibodies based on affinity constant and epitope.
    Uchiyama S; Suzuki Y; Otake K; Yokoyama M; Ohta M; Aikawa S; Komatsu M; Sawada T; Kagami Y; Morishima Y; Fukui K
    Cancer Sci; 2010 Jan; 101(1):201-9. PubMed ID: 19930155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy.
    Lv Y; Du Y; Li K; Ma X; Wang J; Du T; Ma Y; Teng Y; Tang W; Ma R; Wu J; Wu J; Feng J
    Cell Commun Signal; 2023 Jan; 21(1):16. PubMed ID: 36691066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology.
    Oflazoglu E; Audoly LP
    MAbs; 2010; 2(1):14-9. PubMed ID: 20081379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing.
    Jeon MJ; Yu ES; Choi CW; Kim DS
    Korean J Intern Med; 2023 Nov; 38(6):893-902. PubMed ID: 37599392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy.
    Griffioen M; van Egmond EH; Kester MG; Willemze R; Falkenburg JH; Heemskerk MH
    Haematologica; 2009 Sep; 94(9):1316-20. PubMed ID: 19734426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of primary central nervous system lymphoma with induction of complement-dependent cytotoxicity by intraventricular administration of autologous-serum-supplemented rituximab.
    Takami A; Hayashi T; Kita D; Nishimura R; Asakura H; Nakao S
    Cancer Sci; 2006 Jan; 97(1):80-3. PubMed ID: 16367925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential effect of statins on rituximab immunotherapy.
    Cragg MS
    PLoS Med; 2008 Mar; 5(3):e77. PubMed ID: 18366253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.